Managing neuroinflammation could represent a promising new therapeutic approach in glaucoma
Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care
The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod
Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions
Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2
Nicox SA shares research findings from NCX 470 Mont Blanc Phase 3 glaucoma trial
The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension
